ScreenerHero

SEPN Septerna, Inc.

NAS · US · Healthcare · Biotechnology · septerna.com
35.44USD-1.57%Mkt Cap: 1.68B $P/E: —

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$58.08BUSDP/E 35.4
ARGX
argenx SE
$48.23BUSDP/E 31.4
RVMD
Revolution Medicines, Inc.
$43.05BUSD
UCB
UCB SA
$41.82BUSDP/E 17.8
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.68B USD
Enterprise Value1.32B USD
Revenue (TTM)98.88M USD
Gross Profit98.88M USD
Net Income (TTM)-48.88M USD
Revenue/Share2.21 USD
Last Price35.44 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees123
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.38
PEG—
EV/EBITDA-24.18
EV/Revenue13.30
P/S16.84
P/B4.21
EPS (TTM)-0.51
EPS (Forward)-1.94
52W Range
17.5553% of range51.09
52W High51.09 USD
52W Low17.55 USD
Profitability
Gross Margin100.00%
Oper. Margin-62.95%
EBITDA Margin-55.01%
Profit Margin-106.37%
ROE-12.80%
ROA-8.20%
Growth
Revenue Growth22375.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF110.19M USD
CapEx (TTM)518.00K USD
FCF Margin29.88%
FCF Yield1.76%
Net Debt-349.78M USD
Net Debt/EBITDA6.43
Balance Sheet
Debt/Equity0.06
Current Ratio5.00
Quick Ratio4.89
Book Value/Sh8.47 USD
Cash/Share7.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)54.22 USD
Upside (mean)+53.0%
Target Range48.00 USD – 62.00 USD
48.00+53.0% to mean62.00
# Analysts9
Ownership
Shares Out.46.68M
Float26.41M
Insiders2.94%
Institutions99.05%
Short Interest
Short Ratio8.6d
Short % Float11.85%
Short % Out.6.20%
Shares Short2.89M
Short (prev mo.)2.87M
Technical
SMA 5039.18 (-9.5%)
SMA 20030.94 (+14.5%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)365.17K
Avg Vol (10d)387.86K
Technical Indicators
RSI (14)39.6
MACD-0.5248
MACD Signal-0.2200
MACD Hist.-0.3048
BB Upper40.67 USD
BB Middle38.39 USD
BB Lower36.12 USD
BB Width11.86%
ATR (14)1.979 USD
Vol Ratio (20d)2.77x